Market Place
Sourcing Support
Capricor Shares Sink as US FDA Declines to Approve Cell Therapy
14 Jul 2025 //
REUTERS
Capricor Shares Sink After FDA Declines Approval for Muscle Drug
11 Jul 2025 //
REUTERS
Capricor Says FDA May Not Convene Panel for Co`s Cell Therapy
25 Jun 2025 //
REUTERS
Capricor Therapeutics: Positive 4-Year Data from HOPE-2 Study
20 Jun 2025 //
GLOBENEWSWIRE
Capricor Gets Orphan Drug Designation For BMD, Advances DMD
17 Jun 2025 //
GLOBENEWSWIRE
Capricor reports FDA inspection findings on Form 483
11 Jun 2025 //
TIPRANKS
Capricor Therapeutics Announces Regulatory Updates for DMD
11 Jun 2025 //
GLOBENEWSWIRE
Capricor Therapeutics Appoints Michael Binks as CMO
13 May 2025 //
GLOBENEWSWIRE
Capricor Therapeutics Reports Q1 2025 Financial Results
13 May 2025 //
GLOBENEWSWIRE
Capricor Therapeutics to Present Q1 2025 Results on May 13
06 May 2025 //
GLOBENEWSWIRE
US FDA panel for Capricor Therapeutics` DMD cell therapy
06 May 2025 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at 2025 Piper Sandler Cardio Day
01 Apr 2025 //
GLOBENEWSWIRE
Capricor Therapeutics Reports Q4 & Full-Year 2024 Results
19 Mar 2025 //
GLOBENEWSWIRE
Capricor Therapeutic Show Long-Term Efficacy of Deramiocel for DMD
17 Mar 2025 //
GLOBENEWSWIRE
Capricor Therapeutics to Present Q4 and Full Year 2024 Financial
11 Mar 2025 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Leerink`s Healthcare Conf. 2025
07 Mar 2025 //
GLOBENEWSWIRE
Capricor Gets FDA Priority Review For Deramiocel In DMD
04 Mar 2025 //
GLOBENEWSWIRE
Capricor Therapeutic to Participate in Upcoming Investor Conference
10 Feb 2025 //
GLOBENEWSWIRE
Capricor Completes Submission of BLA for Deramiocel for DMD
02 Jan 2025 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Upcoming Investor Conferences
02 Dec 2024 //
GLOBENEWSWIRE
Capricor Granted Orphan Drug And ATMP Status For Deramiocel
20 Nov 2024 //
GLOBENEWSWIRE
Capricor Reports Q3 2024 Results & Corporate Update
13 Nov 2024 //
GLOBENEWSWIRE
Capricor to Present Exosome Platform Updates at 2024 AEV Annual Meeting
12 Nov 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to Present Q3 2024 Results on Nov 13
05 Nov 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Closes Underwritten Public Offering
18 Oct 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Prices $75 Million Public Offering of Stock
17 Oct 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Proposes Public Offering Of Common Stock
16 Oct 2024 //
GLOBENEWSWIRE
Capricor shares more data for DMD therapy after initiating BLA
11 Oct 2024 //
FIERCE BIOTECH
Capricor Announces Data from Study in DMD at Muscle Society Congress
11 Oct 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Initiates Rolling BLA For Deramiocel In DMD
09 Oct 2024 //
GLOBENEWSWIRE
Capricor To Present Long-Term Data From HOPE-2 Study At Congress
04 Oct 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to File Application for Deramiocel Approval
24 Sep 2024 //
GLOBENEWSWIRE
Capricor To Provide Duchenne Muscular Dystrophy Update
23 Sep 2024 //
GLOBENEWSWIRE
Capricor sells Europe rights to DMD therapy for $35M FDA application approaches
19 Sep 2024 //
FIERCE BIOTECH
Capricor Signs Term Sheet With Nippon Shinyaku for Europe
17 Sep 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
06 Sep 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Reports Q2 2024 Results And Corporate Update
07 Aug 2024 //
GLOBENEWSWIRE
Capricor Therapeutics To Report Q2 2024 Results On August 7
31 Jul 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
01 Jul 2024 //
GLOBENEWSWIRE
Capricor Reports Long-Term Benefits Of Deramiocel In Duchenne Muscular Dystrophy
28 Jun 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
25 Jun 2024 //
GLOBENEWSWIRE
CORRECTION: Capricor Therapeutics
25 Jun 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces +ve Type-B Meeting with FDA for CAP-1002 Program
11 Jun 2024 //
GLOBENEWSWIRE
Capricor: Positive 3-Year CAP-1002 Efficacy In Duchenne Muscular Dystrophy
04 Jun 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Q1 2024 Financials, Corporate Update
13 May 2024 //
GLOBENEWSWIRE
Capricor Exosome Platform Update At ASGCT Annual Meeting 2024
09 May 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
08 May 2024 //
GLOBENEWSWIRE
Capricor To Present Q1 2024 Results, Updates On May 13
06 May 2024 //
GLOBENEWSWIRE
Capricor`s Positive FDA Meeting for DMD Drug CAP-1002
24 Apr 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Upcoming Investor Conferences
21 Mar 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Presents at 2024 MDA Clinical & Scientific Conference
06 Mar 2024 //
GLOBENEWSWIRE
Capricor Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA
27 Feb 2024 //
GLOBENEWSWIRE
Capricor to Present Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production
20 Feb 2024 //
GLOBENEWSWIRE
Capricor Announces Collaboration with the National Institutes of Health
24 Jan 2024 //
GLOBENEWSWIRE
Capricor Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002
11 Dec 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Capricor Therapeutics to Present Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar
19 Oct 2023 //
GLOBENEWSWIRE
